Angela L Nocera1, Sarina K Mueller2, Alan D Workman3, Dawei Wu3, Kristen McDonnell3, Peter M Sadow4, Mansoor M Amiji5, Benjamin S Bleier6. 1. Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Mass; Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Mass. 2. Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Mass; Department of Otolaryngology/Head and Neck Surgery, University of Erlangen-Nuremberg, Nuremberg, Germany. 3. Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Mass. 4. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. 5. Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Mass. 6. Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Mass. Electronic address: benjamin_bleier@meei.harvard.edu.
Abstract
BACKGROUND: Cystatin SN (CST1) and cystatin SA (CST2) are cysteine protease inhibitors that protect against allergen, viral, and bacterial proteases. Cystatins are overexpressed in the setting of allergic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP); however, their role in promoting type 2 inflammation remains poorly characterized. OBJECTIVE: The purpose of this study was to use integrated poly-omics and a murine exposure model to explore the link between cystatin overexpression in CRSwNP and type 2 inflammation. METHODS: In this institutional review board- and institutional animal care and use committee-approved study, we compared tissue, exosome, and mucus CST1 and CST2 between CRSwNP and controls (n = 10 per group) by using matched whole exome sequencing, transcriptomic, proteomic, posttranslational modification, histologic, functional, and bioinformatic analyses. C57/BL6 mice were dosed with 3.9 μg/mL of CST1 or PBS intranasally for 5 to 18 days in the presence or absence of epithelial ABCB1a knockdown. Inflammatory cytokines were quantified by using Quansys multiplex assays or ELISAs. RESULTS: Of the 1305 proteins quantified, CST1 and CST2 were among the most overexpressed protease inhibitors in tissue, exosome, and mucus samples; they were localized to the epithelial layer. Multiple posttranslational modifications were identified in the polyp tissue. Exosomal CST1 and CST2 were strongly and significantly correlated with eosinophils and Lund-Mackay scores. Murine type 2 cytokine secretion and TH2 cell infiltration increased in a time-dependent manner following CST1 exposure and was abrogated by epithelial knockdown of ABCB1a, a regulator of epithelial cytokine secretion. CONCLUSION: CST1 is a potent upstream initiator of epithelial-derived type 2 inflammation in CRSwNP. Therapeutic strategies targeting CST activity and its associated posttranslational modifications deserve further interrogation.
BACKGROUND: Cystatin SN (CST1) and cystatin SA (CST2) are cysteine protease inhibitors that protect against allergen, viral, and bacterial proteases. Cystatins are overexpressed in the setting of allergic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP); however, their role in promoting type 2 inflammation remains poorly characterized. OBJECTIVE: The purpose of this study was to use integrated poly-omics and a murine exposure model to explore the link between cystatin overexpression in CRSwNP and type 2 inflammation. METHODS: In this institutional review board- and institutional animal care and use committee-approved study, we compared tissue, exosome, and mucus CST1 and CST2 between CRSwNP and controls (n = 10 per group) by using matched whole exome sequencing, transcriptomic, proteomic, posttranslational modification, histologic, functional, and bioinformatic analyses. C57/BL6 mice were dosed with 3.9 μg/mL of CST1 or PBS intranasally for 5 to 18 days in the presence or absence of epithelial ABCB1a knockdown. Inflammatory cytokines were quantified by using Quansys multiplex assays or ELISAs. RESULTS: Of the 1305 proteins quantified, CST1 and CST2 were among the most overexpressed protease inhibitors in tissue, exosome, and mucus samples; they were localized to the epithelial layer. Multiple posttranslational modifications were identified in the polyp tissue. Exosomal CST1 and CST2 were strongly and significantly correlated with eosinophils and Lund-Mackay scores. Murine type 2 cytokine secretion and TH2 cell infiltration increased in a time-dependent manner following CST1 exposure and was abrogated by epithelial knockdown of ABCB1a, a regulator of epithelial cytokine secretion. CONCLUSION: CST1 is a potent upstream initiator of epithelial-derived type 2 inflammation in CRSwNP. Therapeutic strategies targeting CST activity and its associated posttranslational modifications deserve further interrogation.
Authors: Dana V Wallace; Mark S Dykewicz; David I Bernstein; Joann Blessing-Moore; Linda Cox; David A Khan; David M Lang; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher C Randolph; Diane Schuller; Sheldon L Spector; Stephen A Tilles Journal: J Allergy Clin Immunol Date: 2008-08 Impact factor: 10.793
Authors: Marcel M Miyake; Angela Nocera; Patricia Levesque; Rong Guo; Christine A Finn; Jeremy Goldfarb; Stacey Gray; Eric Holbrook; Nicolas Busaba; Jose Eduardo L Dolci; Benjamin S Bleier Journal: J Allergy Clin Immunol Date: 2017-01-23 Impact factor: 10.793
Authors: Claus Bachert; Joseph K Han; Martin Desrosiers; Peter W Hellings; Nikhil Amin; Stella E Lee; Joaquim Mullol; Leon S Greos; John V Bosso; Tanya M Laidlaw; Anders U Cervin; Jorge F Maspero; Claire Hopkins; Heidi Olze; G Walter Canonica; Pierluigi Paggiaro; Seong H Cho; Wytske J Fokkens; Shigeharu Fujieda; Mei Zhang; Xin Lu; Chunpeng Fan; Steven Draikiwicz; Siddhesh A Kamat; Asif Khan; Gianluca Pirozzi; Naimish Patel; Neil M H Graham; Marcella Ruddy; Heribert Staudinger; David Weinreich; Neil Stahl; George D Yancopoulos; Leda P Mannent Journal: Lancet Date: 2019-09-19 Impact factor: 79.321
Authors: Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N Brody; Jeff Carter; Andrew B Dalby; Bruce E Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R Keeney; Nancy Kim; Tad H Koch; Stephan Kraemer; Luke Kroiss; Ngan Le; Daniel Levine; Wes Lindsey; Bridget Lollo; Wes Mayfield; Mike Mehan; Robert Mehler; Sally K Nelson; Michele Nelson; Dan Nieuwlandt; Malti Nikrad; Urs Ochsner; Rachel M Ostroff; Matt Otis; Thomas Parker; Steve Pietrasiewicz; Daniel I Resnicow; John Rohloff; Glenn Sanders; Sarah Sattin; Daniel Schneider; Britta Singer; Martin Stanton; Alana Sterkel; Alex Stewart; Suzanne Stratford; Jonathan D Vaught; Mike Vrkljan; Jeffrey J Walker; Mike Watrobka; Sheela Waugh; Allison Weiss; Sheri K Wilcox; Alexey Wolfson; Steven K Wolk; Chi Zhang; Dom Zichi Journal: PLoS One Date: 2010-12-07 Impact factor: 3.240
Authors: Richard R Orlandi; Todd T Kingdom; Timothy L Smith; Benjamin Bleier; Adam DeConde; Amber U Luong; David M Poetker; Zachary Soler; Kevin C Welch; Sarah K Wise; Nithin Adappa; Jeremiah A Alt; Wilma Terezinha Anselmo-Lima; Claus Bachert; Fuad M Baroody; Pete S Batra; Manuel Bernal-Sprekelsen; Daniel Beswick; Neil Bhattacharyya; Rakesh K Chandra; Eugene H Chang; Alexander Chiu; Naweed Chowdhury; Martin J Citardi; Noam A Cohen; David B Conley; John DelGaudio; Martin Desrosiers; Richard Douglas; Jean Anderson Eloy; Wytske J Fokkens; Stacey T Gray; David A Gudis; Daniel L Hamilos; Joseph K Han; Richard Harvey; Peter Hellings; Eric H Holbrook; Claire Hopkins; Peter Hwang; Amin R Javer; Rong-San Jiang; David Kennedy; Robert Kern; Tanya Laidlaw; Devyani Lal; Andrew Lane; Heung-Man Lee; Jivianne T Lee; Joshua M Levy; Sandra Y Lin; Valerie Lund; Kevin C McMains; Ralph Metson; Joaquim Mullol; Robert Naclerio; Gretchen Oakley; Nobuyoshi Otori; James N Palmer; Sanjay R Parikh; Desiderio Passali; Zara Patel; Anju Peters; Carl Philpott; Alkis J Psaltis; Vijay R Ramakrishnan; Murugappan Ramanathan; Hwan-Jung Roh; Luke Rudmik; Raymond Sacks; Rodney J Schlosser; Ahmad R Sedaghat; Brent A Senior; Raj Sindwani; Kristine Smith; Kornkiat Snidvongs; Michael Stewart; Jeffrey D Suh; Bruce K Tan; Justin H Turner; Cornelis M van Drunen; Richard Voegels; De Yun Wang; Bradford A Woodworth; Peter-John Wormald; Erin D Wright; Carol Yan; Luo Zhang; Bing Zhou Journal: Int Forum Allergy Rhinol Date: 2021-03 Impact factor: 5.426